Novartis AG (NVSEF) Operating cash flow 2016–2025
Novartis AG (NVSEF) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$19.1BFY2025 · since FY2016: $11.5B → $19.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $19.1B | +8.7% |
| FY2024 | $17.6B | +21.9% |
| FY2023 | $14.5B | +1.6% |
| FY2022 | $14.2B | -5.5% |
| FY2021 | $15.1B | +10.4% |
| FY2020 | $13.7B | +0.2% |
| FY2019 | $13.6B | -4.5% |
| FY2018 | $14.3B | +13.1% |
| FY2017 | $12.6B | +10.0% |
| FY2016 | $11.5B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NVSEF financial trends
NVSEF RevenueNVSEF Net incomeNVSEF Net marginNVSEF Gross profitNVSEF Gross marginNVSEF Operating incomeNVSEF Operating marginNVSEF Free cash flowNVSEF Capital expendituresNVSEF Return on equityNVSEF Stock buybacksNVSEF Dividends paidNVSEF Total assetsNVSEF Total liabilitiesNVSEF Shareholders’ equityNVSEF overview →